Baxter International Inc. (NYSE:BAX) Shares Bought by Liberty Capital Management Inc.

Liberty Capital Management Inc. raised its position in Baxter International Inc. (NYSE:BAX) by 0.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 28,707 shares of the medical instruments supplier’s stock after buying an additional 107 shares during the period. Liberty Capital Management Inc.’s holdings in Baxter International were worth $1,741,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Pure Financial Advisors Inc. boosted its stake in Baxter International by 0.3% in the first quarter. Pure Financial Advisors Inc. now owns 7,459 shares of the medical instruments supplier’s stock worth $387,000 after buying an additional 22 shares during the period. Quadrant Capital Group LLC boosted its stake in Baxter International by 1.3% in the first quarter. Quadrant Capital Group LLC now owns 2,344 shares of the medical instruments supplier’s stock worth $113,000 after buying an additional 31 shares during the period. Dumont & Blake Investment Advisors LLC boosted its stake in Baxter International by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 12,786 shares of the medical instruments supplier’s stock worth $663,000 after buying an additional 40 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management boosted its stake in Baxter International by 0.3% in the first quarter. Livingston Group Asset Management CO operating as Southport Capital Management now owns 18,079 shares of the medical instruments supplier’s stock worth $938,000 after buying an additional 54 shares during the period. Finally, Reliance Trust Co. of Delaware boosted its stake in Baxter International by 1.1% in the first quarter. Reliance Trust Co. of Delaware now owns 5,743 shares of the medical instruments supplier’s stock worth $298,000 after buying an additional 63 shares during the period. 85.08% of the stock is currently owned by institutional investors.

Baxter International Inc. (NYSE:BAX) traded up 0.22% during mid-day trading on Friday, hitting $59.84. 2,213,852 shares of the stock were exchanged. The company’s 50-day moving average price is $60.89 and its 200 day moving average price is $55.35. Baxter International Inc. has a 52 week low of $43.13 and a 52 week high of $63.14. The firm has a market capitalization of $32.61 billion, a price-to-earnings ratio of 36.31 and a beta of 0.66.

Baxter International (NYSE:BAX) last announced its earnings results on Wednesday, July 26th. The medical instruments supplier reported $0.63 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.06. Baxter International had a net margin of 8.85% and a return on equity of 14.82%. The company had revenue of $2.61 billion during the quarter, compared to analyst estimates of $2.59 billion. During the same quarter last year, the firm posted $0.46 earnings per share. Baxter International’s revenue was up .8% compared to the same quarter last year. Equities research analysts expect that Baxter International Inc. will post $2.39 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 2nd. Stockholders of record on Friday, September 1st will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 1.07%. The ex-dividend date is Wednesday, August 30th. Baxter International’s payout ratio is 38.79%.

ILLEGAL ACTIVITY WARNING: “Baxter International Inc. (NYSE:BAX) Shares Bought by Liberty Capital Management Inc.” was first posted by BNB Daily and is the sole property of of BNB Daily. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/13/baxter-international-inc-nysebax-shares-bought-by-liberty-capital-management-inc-updated.html.

A number of equities research analysts recently commented on the stock. Royal Bank Of Canada lifted their price target on shares of Baxter International from $55.00 to $58.00 and gave the stock a “sector perform” rating in a report on Thursday, April 27th. BMO Capital Markets reissued a “hold” rating and set a $55.00 target price on shares of Baxter International in a report on Thursday, April 27th. Cantor Fitzgerald set a $70.00 target price on shares of Baxter International and gave the company a “buy” rating in a report on Wednesday, July 26th. Cowen and Company reissued a “market perform” rating and set a $68.00 target price (up previously from $66.00) on shares of Baxter International in a report on Thursday, July 27th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $75.00 price target (up previously from $67.00) on shares of Baxter International in a report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $65.33.

In other news, Director Carole J. Shapazian sold 2,618 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $57.92, for a total value of $151,634.56. Following the completion of the transaction, the director now owns 9,848 shares of the company’s stock, valued at $570,396.16. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.05% of the company’s stock.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply